Zobrazeno 1 - 10
of 53
pro vyhledávání: '"A. Martinez-Tobed"'
Publikováno v:
Xenobiotica. 36:807-823
Almotriptan is a new highly potent selective 5-HT1B/1D receptor agonist developed for the treatment of migraine, and the disposition of almotriptan in different animal species is now addressed in the current study. Almotriptan was well absorbed in ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cc2c181a4be2444cacd88b7239886be
https://doi.org/10.1080/00498250600802508
https://doi.org/10.1080/00498250600802508
Publikováno v:
Drug Metabolism and Disposition. 31:404-411
Almotriptan is a novel highly selective 5-hydroxytryptamine(1B/1D) agonist developed for the acute oral treatment of migraine. The in vitro metabolism of almotriptan has been investigated using human liver subcellular fractions and cDNA-expressed hum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a06c83c03eba8615ba6dc24c352bded1
https://doi.org/10.1124/dmd.31.4.404
https://doi.org/10.1124/dmd.31.4.404
Publikováno v:
The Journal of Clinical Pharmacology. 42:1303-1310
Absolute bioavailability, pharmacokinetics, and urinary excretion of almotriptan, a novel 5-HT(1B/1D) receptor agonist, were studied in 18 healthy males following single intravenous (i.v.) (3 mg), subcutaneous (s.c.) (6 mg), and oral (25 mg) doses. V
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5cd0023e26226b911b3645e548f05dc
https://doi.org/10.1177/0091270002042012006
https://doi.org/10.1177/0091270002042012006
Publikováno v:
International journal of clinical pharmacology and therapeutics. 44(4)
This open, randomized, crossover, single-dose clinical trial evaluated the possible pharmacokinetic interaction between a single oral dose of almotriptan 25 mg, a 5-HT 1B/1D receptor agonist for the acute treatment of migraine, and food intake in hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34d3c8c8cd0820039d1f90da8b097431
https://pubmed.ncbi.nlm.nih.gov/16625988
https://pubmed.ncbi.nlm.nih.gov/16625988
Pharmacokinetic and pharmacodynamic studies of the histamine H1-receptor antagonist ebastine in dogs
Publikováno v:
The Journal of pharmacy and pharmacology. 46(7)
The pharmacokinetics and pharmacodynamics of ebastine at single oral doses of 10 and 20 mg were studied in six healthy beagle dogs. Plasma concentrations of the active metabolite of ebastine were measured at predetermined times after the dose. At the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e22aa59b3950cffe50d4746349b3b5af
https://pubmed.ncbi.nlm.nih.gov/7996390
https://pubmed.ncbi.nlm.nih.gov/7996390
Autor:
J.A. Gutiérrez, I.T. Molina-Martinez, A. Martinez-Tobed, Cadorniga R, R. Herrero, J.L. Fábregas, J.M. Iglesias
Publikováno v:
Journal of pharmaceutical sciences. 82(2)
We studied the influence of administration route on the biopharmaceutical behavior of etodolac. The levels obtained in plasma when the same dose of etodolac is administered orally (tablets, dosage form A) and rectally (suppositories, dosage form B) w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d7b93e4ca8e8e89b57a1b00dedbdf5d
https://pubmed.ncbi.nlm.nih.gov/8445537
https://pubmed.ncbi.nlm.nih.gov/8445537
Autor:
R, Cadorniga, R, Herrero, E, Barcia, I T, Molina, J A, Guitierrez, J L, Fabregas, A, Martinez-Tobed
Publikováno v:
European journal of drug metabolism and pharmacokinetics.
The present study describes the pharmacokinetic behaviour of a new dosage form of etodolac not available in the Spanish market: suppositories. Rectal administration was chosen as an alternative for the oral route. The dose used was 200 mg. The pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a4c22110600fdd78802a93a156b5274
https://pubmed.ncbi.nlm.nih.gov/1840326
https://pubmed.ncbi.nlm.nih.gov/1840326
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.